You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB
SBC: CELLF-BIO LLC Topic: 300Project Summary/Abstract:Fecal incontinence (FI), the involuntary soiling of various amounts of liquid and solid stool, is often devastating from a social, psychological, and hygiene perspective. Men and women suffer from FI equally with a range of 2 - 6% in people aged 20 - 30 years. The prevalence increases to over 15% in people older than 70 years1. FI may result from an isolated or combined lo ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeting leukocyte metabolism to treat human autoimmune disease
SBC: Immunext, Inc. Topic: RImmuNext has defined an anti-MCT1 monoclonal antibody (mAb) that will be developed for the treatment of human autoimmune disease. The membrane monocarboxylate nutrient transporter SLC16A1 (MCT1) is a multi-pass transmembrane protein responsible for the facilitated transport of critical metabolites, including products of glycolysis: lactate, pyruvate and ketones. Our strong preliminary data support ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Green Monopropellant Thruster TRL Maturation Scaling Effort
SBC: CREARE LLC Topic: MDA12T008Diode-Pumped Alkali Lasers (DPALs) have great potential for high-energy lasers. Proper design of these systems is challenging because many interrelated processes impact their performance, and critical kinetic rate coefficients are not well known. In response, our team is developing a comprehensive physics-based analysis/design tool, and experimentally determining key kinetic rate coefficients. The ...
STTR Phase II 2018 Department of DefenseMissile Defense Agency -
CometChip: Development of a high throughput DNA damage assay in hepatocytes
SBC: INTEGRATED LABORATORY SYSTEMS, LLC Topic: NIEHSAn estimated 10,000 animals are used in toxicology safety assessments to meet all regulatory requirements with testing spanning 5 to 10 yrs and exceeding $10 million dollars. There is a critical need to reduce reliance on animal testing and to develop highly predictive human-based biological models for safety assessments. Replacement of traditional animal toxicity tests for toxicology safety asses ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Point-of-care device to identify patients at risk for preeclampsia
SBC: AFFINERGY, LLC Topic: NAlthough international trends for maternal mortality have shown an overall decline, maternal mortality rates in the United States have increased by andgt;25% since 2000. One of the leading causes for this increase is preeclampsia, a complication of pregnancy characterized by elevated blood pressure, proteinuria, and endothelial dysfunction involving multiple organ systems. Worldwide, preeclampsia ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
AM for Missile Defense
SBC: AURA TECHNOLOGIES, LLC Topic: MDA16013We propose to create a system that integrates simulation capabilities into design software that will allow MDA the ability to quickly vet new AM parts with 150x improvement in efficiency. This will allow more machine up time, less cost, and faster design iterations.
SBIR Phase II 2018 Department of DefenseAir Force -
Administrative Supplement for the Evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer
SBC: CIVATECH ONCOLOGY INC Topic: NCIParent Award: R44CA217587 Clinical Evaluation of the novel, Uni-directional Pd-103 CivaSheet for Lung Cancers CivaTech Oncology’s mission is to provide improved radiation therapy directly to localized tumors. The Company has developed a novel, polymer-encapsulated, membrane-like radiation source that emits radiation on only one side of the device – CivaSheet®. This directional source is compa ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Device for rapid extraction of rare pathogens from raw samples
SBC: Redbud Labs, Inc. Topic: RABSTRACTRedbud Labs proposes to develop a low costintegrated microfluidic system to purify and concentrate pathogens directly frommL of whole bloodwith the goal of improving the sensitivity of downstream blood culture and molecular diagnostic assays used in sepsis diagnosis and treatmentPhase I studies have demonstrated that our technologybased on actuated surface attached postsASAPscan achieve hi ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Accelerated discovery of methylation targeted therapeutic development
SBC: Epicypher, Inc. Topic: 102PROJECT SUMMARYNucleosomesNucsare the repeating units of chromatinmade up of DNA wrapped around a histone octamerChanges in chromatin structurefunction can dramatically impact downstream gene expression and cellular physiologydriving oncogenic reprogramming and cancer progressionThis epigenetic regulation of chromatin is controlled by two major modificationshistone post translational modifications ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension
SBC: VASCULAR BIOSCIENCES, INC. Topic: NHLBIPUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health